Blastic plasmacytoid dendritic cell neoplasm Blastic plasmacytoid dendritic cell neoplasm is a rare type of
myeloid cancer in which malignant pDCs infiltrate the skin, bone marrow, central nervous system, and other tissues. Typically, the disease presents with skin lesions (e.g. nodules, tumors,
papules, bruise-like patches, and/or ulcers) that most often occur on the head, face, and upper torso. This presentation may be accompanied by cPC infiltrations into other tissues to result in swollen
lymph nodes, enlarged liver, enlarged spleen, symptoms of
central nervous system dysfunction, and similar abnormalities in breasts, eyes, kidneys, lungs, gastrointestinal tract, bone, sinuses, ears, and/or testes. Blastic plasmacytoid dendritic cell neoplasm has a high rate of recurrence following initial treatments with various
chemotherapy regimens. In consequence, the disease has a poor overall prognosis and newer
chemotherapeutic and novel
non-chemotherapeutic drug regimens to improve the situation are under study.
Viral infection HIV, which causes
AIDS, can bind to dendritic cells via various receptors expressed on the cell. The best studied example is
DC-SIGN (usually on MDC subset 1, but also on other subsets under certain conditions; since not all dendritic cell subsets express DC-SIGN, its exact role in sexual HIV-1 transmission is not clear). When the dendritic cell takes up HIV and then travels to the lymph node, the virus can be transferred to helper CD4+ T-cells, contributing to the developing infection. This infection of dendritic cells by HIV explains one mechanism by which the virus could persist after prolonged
HAART. Many other viruses, such as the
SARS virus, seem to use DC-SIGN to 'hitchhike' to its target cells. However, most work with virus binding to DC-SIGN expressing cells has been conducted using in vitro derived cells such as moDCs. The physiological role of DC-SIGN in vivo is more difficult to ascertain.
Cancer Dendritic cells are usually not abundant at tumor sites, but increased densities of populations of dendritic cells have been associated with better clinical outcome, suggesting that these cells can participate in controlling cancer progression. Lung cancers have been found to include four different subsets of dendritic cells: three classical dendritic cell subsets and one plasmacytoid dendritic cell subset. At least some of these dendritic cell subsets can activate CD4+ helper T cells and
CD8+ cytotoxic T cells, which are immune cells that can also suppress
tumor growth. However, dendritic cell activity is commonly suppressed by regulatory T cells and multiple other factors. Dendritic cell stimulating treatments, such as dendritic cell based vaccinations, have been emerging as a treatment with varying success. In experimental models, dendritic cells have also been shown to contribute to the success of cancer immunotherapies, for example with the immune checkpoint blocker anti-PD-1.
Autoimmunity Altered function of dendritic cells is also known to play a major or even key role in
allergy and
autoimmune diseases like
lupus erythematosus and inflammatory bowel diseases (
Crohn's disease and
ulcerative colitis). ==Other animals==